Clinical trials: Advanced Malignant Tumors
Advanced Solid Tumors
A Study of ASP1951 in Subjects With Advanced Solid Tumors
The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or…
- Trial name
- NCT03799003
- Testing
- ASP1951, pembrolizumab
- Where
- 32 sites in United States, Canada and 2 more
- Volunteers
- 119 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Colorectal Neoplasms, Advanced Metastatic Colorectal Cancer
Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)
Patients are being asked to participate in this study who have colorectal cancer that has come back after initial treatment. The investigators want to improve treatment in patients with this disease.
- Trial name
- NCT01909362
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- US Oncology Research
Neoplasms
A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer
This study is designed to provide continued access to intravenous (IV) Herceptin and to evaluate long-term outcomes and overall safety in participants with stable disease and human epidermal growth factor 2 (HER2)-overexpressing…
- Trial name
- NCT02721641
- Testing
- Herceptin
- Where
- 41 sites in Australia, Belgium and 15 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Soft Tissue Sarcoma, Colorectal Cancer
A Safety Study of SGN-CD47M in Patients With Solid Tumors
This trial will study SGN-CD47M to find out whether it is an effective treatment for different types of solid tumors and what side effects (unwanted effects) may occur. The study will have two parts.
- Conditions
- Soft Tissue Sarcoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Carcinoma
- Trial name
- NCT03957096
- Testing
- SGN-CD47M
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Seagen Inc.
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations
TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of TAS-117 in patients with advanced or metastatic solid tumors (excluding primary brain tumors)…
- Trial name
- NCT04770246
- Testing
- TAS-117
- Where
- 8 sites in United States, Austria and 2 more
- Volunteers
- 17 people
- Sponsor
- Taiho Oncology, Inc.
Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including triple negative breast cancer (TNBC), and to determine a recommended Phase 2 dose level for…
- Trial name
- NCT07190469
- Testing
- PQ203
- Where
- 4 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- ProteinQure Inc.
Advanced Solid Tumors
Study of FID-022 in Participants With Advanced Solid Tumors
The goal of this Phase I Clinical Trial is to evaluate the safety and tolerability of FID-022 in patients with advanced solid tumors.
- Trial name
- NCT06694480
- Testing
- FID-022
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Fulgent Pharma LLC.
Advanced Solid Tumor
A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.
This is a first-in-human, 2-part study to investigate the safety, tolerability, pharmacokinetics and efficacy of KM257 by itself and combined with selected chemotherapy agents in patients with advanced HER2-positive or expressing…
- Trial name
- NCT05320874
- Testing
- KM257 Bispecific antibody
- Where
- China
- Volunteers
- 232 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Advanced Cancer, Breast Cancer
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination…
- Conditions
- Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
- Trial name
- PIKture-01 (NCT06239467)
- Testing
- OKI-219, Fulvestrant, Trastuzumab
- Where
- 33 sites in United States, Belgium and 4 more
- Volunteers
- 200 people
- Sponsor
- OnKure, Inc.
Solid Tumor, Adult, Carcinoma, Ovarian Epithelial
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD)…
- Conditions
- Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Endometrial Cancer
- Trial name
- NCT04196257
- Testing
- BP1001-A (Liposomal Grb2 Antisense Oligonucleotide), BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Bio-Path Holdings, Inc.
Advanced Solid Tumors and Hematologic Malignancies
Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies
This is a nonrandomized, open-label, multicenter, phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of CM369 in subjects with advanced solid tumors and Hematologic…
- Trial name
- NCT05690581
- Testing
- CM369
- Where
- 3 sites in China
- Volunteers
- 146 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Advanced Solid Tumors
Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody
This was a dose verification, pharmacokinetic (PK) assessment of products derived from two manufacturing processes and scales (500L-FMP and 2000L-FMP; FMP: Final Manufacturing Process) and indication expansion clinical study of…
- Trial name
- NCT04068519
- Testing
- Tislelizumab
- Where
- 12 sites in China
- Volunteers
- 300 people
- Sponsor
- BeiGene
Solid Tumor
A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors
This trial is a multi-center, open-label, phase I, dose escalation study of PEP02 (liposomal encapsulated irinotecan) in combination with 5-FU and LV in patients with advanced solid tumors.
- Trial name
- NCT02884128
- Testing
- PEP02, 5-FU, LV
- Volunteers
- 16 people
- Sponsor
- PharmaEngine
Locally Advanced or Metastatic Solid Tumors, Squamous-cell Non-small Cell Lung Cancer
HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors
This Phase1, multicenter, first-in-human, open-label, dose-escalation, and dose expansion study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of HLX35 administered as a single-agent…
- Trial name
- NCT05360381
- Testing
- HLX35
- Where
- 2 sites in China
- Volunteers
- 82 people
- Sponsor
- Shanghai Henlius Biotech
Cancer
A Dose-Finding Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7050 given orally in patients with advanced solid tumors.
- Trial name
- NCT00869895
- Testing
- E7050
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Eisai Inc.
Merkel Cell Carcinoma, Small Cell Lung Cancer
Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
This is a Phase 1b/2, multiple-dose study designed to describe safety and efficacy, and to assess PK and immunogenicity of XmAb18087 monotherapy and in combination with pembrolizumab in participants with metastatic Merkel cell…
- Trial name
- NCT04590781
- Testing
- XmAb18087, XmAb18087 ± Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- Xencor, Inc.
Malignant Melanoma
Vaccine Treatment for Advanced Malignant Melanoma
This 2-phase study will determine the safety of treating patients with malignant melanoma with the genetically engineered HyperAcute-Melanoma vaccine.
- Trial name
- NCT00300612
- Testing
- HyperAcute-Melanoma Vaccine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- NewLink Genetics Corporation
Advanced Malignant Tumors
JSKN033 in Chinese Subjects with Advanced Malignant Tumors
This is a phase I/II multicenter study to evaluate the safety and efficacy of JSKN033 in Chinese subjects with unresectable locally advanced/metastatic solid tumors.
- Trial name
- NCT06770881
- Testing
- JSKN033
- Volunteers
- 430 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Refractory Solid Tumors
Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
The purpose of the study is to evaluate the safety and tolerability of BNA035 in order to determine the maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D) and to evaluate the preliminary efficacy for each…
- Trial name
- NCT05150457
- Testing
- BNA035
- Where
- 3 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Binacea Pharma, Inc.
Advanced Solid Tumors
An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors
This is an extension study of ABT-806 for subjects with advanced solid tumors.
- Trial name
- NCT01406119
- Testing
- ABT-806
- Where
- 4 sites in United States, Australia
- Volunteers
- 14 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.